Alaunos Therapeutics Inc.
Company Snapshot
Company Overview
Ziopharm Oncology, in 2022, the company has been renamed as Alaunos Therapeutics. It is a biopharmaceutical company focused on small molecule and synthetic biology approaches to new cancer therapies, seeks to develop and commercialize a diverse portfolio of cancer drugs that can address unmet medical needs. In addition to palifosfamide, the company is working to develop an oral tubulin binding agent to target mitosis and cancer cell migration and an organic arsenic to treat various hematologic and solid cancers.
The company seeks to use DNA as a pharmaceutical agent to treat disease, particularly cancer. The company believes DNA can be used to supplement or alter genes within an individual’s cells as a therapy to treat disease. Palifosfamide is the functional active metabolite of ifosfamide, which has been shown to be effective in treating testicular cancer, sarcoma and lymphoma, but ifosfamide metabolites include acrolein and chloroacetaldehyde, which are both highly toxic.
According to Ziopharm, preclinical studies have shown palifosfamide has activity in leukemia and solid tumor cancers. These studies also indicate that palifosfamide has a better safety profile than ifosfamide, most likely because the drug does not include acrolein and chloroacetaldehyde. The company believes the administration of palifosfamide may avoid many of the toxicities of ifosfamide without compromising the activity of the drug.
The company says the drug could be beneficial for cancer patients suffering from advanced soft-tissue sarcoma, which is incurable and has a short survival window. It could be an alternative to chemotherapy.
In 2007, Ziopharm garnered Orphan Drug status for the drug from the FDA, which allows the firm to have seven years of exclusivity for the drug if it reaches the market, among other benefits, in exchange for developing a drug with a limited market. In February 2012, the FDA accepted Ziopharm’s investigational new drug application for an oral dose of palifosfamide, which the company says could lead to great development opportunities for the drug. The company says an intravenous form of the drug is currently undergoing a randomized, double-blinded, placebo-controlled Phase 3 trial for the treatment of metastatic soft tissue sarcoma in the front-line setting, called PICASSO 3, and is also completing a Phase 1 study in solid tumors, including small cell lung cancer. The drug has further entered into an adaptive Phase 3 trial in extensive SCLC, which began in the second half of 2012 and completed in March 2013. In phase 3 trail, 447 participants were participated. In all, 447 patients were randomly assigned to receive doxorubicin plus palifosfamide (n = 226) or doxorubicin plus placebo (n = 221). Median PFS was 6.0 months for doxorubicin plus palifosfamide and 5.2 months for doxorubicin plus placebo (hazard ratio, 0.86; 95% CI, 0.68 to 1.08; P = .19). Median overall survival was 15.9 months for doxorubicin plus palifosfamide and 16.9 months for doxorubicin plus placebo (hazard ratio, 1.05; 95% CI, 0.79 to 1.39; P = .74). There was a higher incidence of grade 3 to 4 adverse events in the doxorubicin plus palifosfamide arm (63.6% v 50.9%) including a higher rate of febrile neutropenia (21.4% v 12.6%). No significant difference in PFS was observed in patients receiving doxorubicin plus palifosfamide compared with those receiving doxorubicin plus placebo. The observed median PFS and overall survival in this large, international study can serve as a benchmark for future studies of doxorubicin in metastatic soft tissue sarcoma.
Financial Highlights (FY 2025)
This information is available for BCC Research members only.
Alaunos Therapeutics Inc. In Reports
Alaunos Therapeutics Inc. In News
Company's Business Segments
- Product : TCR-T Cell Therapies, Non-viral Cell Engineering Platform, Others
- Service : TCR Discovery and Development, Manufacturing, Partnerships, Others
Applications/End User Industries
- Oncology
- Cell Therapy
- Healthcare
- Diagnostics
- Life Sciences